October 5, 2026 H.C. Wainwright & Co. – Our Universe 4Q26 Catalyst Movers and Shakers September 29, 2026 Maxim Group – Shares Round-Trip on Disappointing Metabolic Disease Study, but Creates Opportunistic Entry Point Ahead of ALS Data by YE26 September 28, 2026 H.C. Wainwright & Co. – Mixed Phase 2 Efficacy Signals Support Potential Evaluation of Tipelukast’s Broader Metabolic Effects September 24, 2026 H.C. Wainwright & Co. – COMBAT-ALS Crosses Final LPLV Milestone; Topline Data on Track by YE26 September 24, 2026 Maxim Group – Last Patient Visit Complete in P2b/3 ALS Study, Top-line Data Expected YE26; P2 Data in Metabolic Disease Expected by end of 3Q September 17, 2026 Roth Capital Partners – MNOV: Initiate at Buy, $6 PT; A Multimodal Mechanism to Power ALS Treatment August 14, 2026 H.C. Wainwright & Co. – Advancing Dual-Asset Pipeline with Two Key Readouts on the Horizon; 2Q26 Results August 14, 2026 Maxim Group – 2Q26 Review & Outlook: Multiple Near-Term Events with Readouts in ALS and Metabolic Disease May 27, 2026 H.C. Wainwright & Co. – Tipelukast Enters Final Stretch Before Key Phase March 23, 2026 Maxim Group – Resumption of Coverage Report
September 29, 2026 Maxim Group – Shares Round-Trip on Disappointing Metabolic Disease Study, but Creates Opportunistic Entry Point Ahead of ALS Data by YE26
Maxim Group – Shares Round-Trip on Disappointing Metabolic Disease Study, but Creates Opportunistic Entry Point Ahead of ALS Data by YE26
September 28, 2026 H.C. Wainwright & Co. – Mixed Phase 2 Efficacy Signals Support Potential Evaluation of Tipelukast’s Broader Metabolic Effects
H.C. Wainwright & Co. – Mixed Phase 2 Efficacy Signals Support Potential Evaluation of Tipelukast’s Broader Metabolic Effects
September 24, 2026 H.C. Wainwright & Co. – COMBAT-ALS Crosses Final LPLV Milestone; Topline Data on Track by YE26
September 24, 2026 Maxim Group – Last Patient Visit Complete in P2b/3 ALS Study, Top-line Data Expected YE26; P2 Data in Metabolic Disease Expected by end of 3Q
Maxim Group – Last Patient Visit Complete in P2b/3 ALS Study, Top-line Data Expected YE26; P2 Data in Metabolic Disease Expected by end of 3Q
September 17, 2026 Roth Capital Partners – MNOV: Initiate at Buy, $6 PT; A Multimodal Mechanism to Power ALS Treatment
August 14, 2026 H.C. Wainwright & Co. – Advancing Dual-Asset Pipeline with Two Key Readouts on the Horizon; 2Q26 Results
H.C. Wainwright & Co. – Advancing Dual-Asset Pipeline with Two Key Readouts on the Horizon; 2Q26 Results
August 14, 2026 Maxim Group – 2Q26 Review & Outlook: Multiple Near-Term Events with Readouts in ALS and Metabolic Disease
Maxim Group – 2Q26 Review & Outlook: Multiple Near-Term Events with Readouts in ALS and Metabolic Disease
